Simon Fletcher
Overview
Explore the profile of Simon Fletcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khair K, Fletcher S, Jenner K, Holland M
Haemophilia
. 2024 Nov;
30(6):1373-1382.
PMID: 39545676
Introduction: Glanzmann thrombasthenia (GT) is a platelet function disorder. Symptoms include bruising and bleeding, which may be severe and life-threatening. The day-to-day experiences of those affected remain poorly documented. Aims:...
2.
Khair K, Fletcher S, Boyton M, Holland M
Res Pract Thromb Haemost
. 2024 Nov;
8(7):102586.
PMID: 39526289
Background: Glanzmann thrombasthenia (GT) is a rare platelet function disorder that results in severe bleeding. We assessed clinical symptoms and psychological parameters to identify the unmet needs associated with GT....
3.
Fletcher S, Eddama O, Anderson M, Meacock R, Wattal V, Allen P, et al.
Health Policy
. 2024 Oct;
150:105166.
PMID: 39393210
The NHS is increasingly turning to the independent sector, primarily to alleviate elective care backlogs. However, implications for the healthcare system, patients and staff are not well understood. This paper...
4.
Fletcher S, Jenner K, Holland M, Khair K
Orphanet J Rare Dis
. 2024 Feb;
19(1):59.
PMID: 38341591
Background: Gene therapy has the potential to offer people with haemophilia (PwH) a life free from bleeding and the burden posed by current treatment regimens. To date, gene therapy has...
5.
Boyce S, Fletcher S, Jones A, Kohli R, Mangles S, Ong M, et al.
Orphanet J Rare Dis
. 2023 Nov;
18(1):366.
PMID: 38007560
With the first gene therapies for haemophilia approved by the European Commission, the US Food and Drug Administration, and the Medicines and Healthcare products Regulatory Agency, it is important to...
6.
Felton T, Pattison N, Fletcher S, Finney S, Walsh T, Dark P
J Intensive Care Soc
. 2023 Aug;
23(1):53-57.
PMID: 37593536
In 2013, a group of clinicians on behalf of the National Institute for Health Research, collaborated with ICU Steps to produce guidance about people being enrolled in more than one...
7.
Fletcher S, Jenner K, Holland M, Khair K
Haemophilia
. 2023 Mar;
29(3):776-783.
PMID: 36882329
Background: Qualitative studies have explored why people with haemophilia (PwH) might consider or forgo gene therapy, the impact it has had on those who have received it, and what support...
8.
Wall C, Xiang H, Palmer B, Chalmers E, Chowdary P, Collins P, et al.
Haemophilia
. 2023 Feb;
29(3):743-752.
PMID: 36811304
Introduction: The UK National Haemophilia Database (NHD) collects data from all UK persons with haemophilia A with inhibitors (PwHA-I). It is well-placed to investigate patient selection, clinical outcomes, drug safety...
9.
Cano-Gamez E, Burnham K, Malick Z, Overend L, Kwok A, Smith D, et al.
Sci Transl Med
. 2022 Nov;
14(669):eabq4433.
PMID: 36322631
Dysregulated host responses to infection can lead to organ dysfunction and sepsis, causing millions of global deaths each year. To alleviate this burden, improved prognostication and biomarkers of response are...
10.
Kitto S, Fantaye A, Davies N, McFadyen A, Rivera J, Birch I, et al.
J Interprof Care
. 2022 Aug;
37(3):515-518.
PMID: 36031805
Interprofessional education (IPE) interventions aiming to promote collaborative competence and improve the delivery of health and social care processes and outcomes continue to evolve. This paper reports on a protocol...